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Abstract
A workshop on “Clinical Translation of Molecular Imaging Probes and Technology” was held
August 2, 2013 in Bethesda, Maryland, organized and supported by the National Institute of
Biomedical Imaging and Bioengineering (NIBIB). This workshop brought together researchers,
clinicians, representatives from pharmaceutical companies, molecular probe developers, and
regulatory science experts. Attendees met to talk over current challenges in the discovery,
validation, and translation of molecular imaging (MI) probes for key clinical applications.
Participants also discussed potential strategies to address these challenges. The workshop
consisted of 4 sessions, with 14 presentations and 2 panel discussions. Topics of discussion
included (1) challenges and opportunities for clinical research and patient care, (2) advances in
molecular probe design, (3) current approaches used by industry and pharmaceutical
companies, and (4) clinical translation of MI probes. In the presentations and discussions, there
were general agreement that while the barriers for validation and translation of MI probes remain
high, there are pressing clinical needs and development opportunities for targets in
cardiovascular, cancer, endocrine, neurological, and inﬂammatory diseases. The strengths of
different imaging modalities, and the synergy of multimodality imaging, were highlighted.
Participants also underscored the continuing need for close interactions and collaborations
between academic and industrial partners, and federal agencies in the imaging probe
development process.
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Introduction
Molecular imaging plays an important role in advancingknowledge about disease pathophysiology, and diag-
nostic tools have been developed based on molecular
imaging probes and technology. As such, the National
Institutes of Health (NIH) has actively supported the
development of molecular imaging probes since 2003 with
targeted programs under a roadmap initiative and initiatives
led by individual institutes. Under the theme “New
Pathways to Discovery and Molecular Libraries and Imaging
Implementation,” a technology development program was
established to encourage the discovery and design of highly
speciﬁc and highly sensitive molecular imaging probes for
basic research and clinical applications. Since then, a
plethora of innovative molecular imaging probes have been
developed with NIH funding and applied to improve the
understanding of disease mechanisms and in some instances
to diagnose and track human disease progression. While few
probes and techniques have been successfully translated for
human application, many have become routine laboratory
tools or are being used in the preclinical arena. Challenges
remain to demonstrate reliable, reproducible, and quantiﬁ-
able in vivo imaging results that are accepted by the medicalCorrespondence to: Christina Liu; e-mail: Christina.liu@nih.gov
community, pharmaceutical industry, and the Food and Drug
Administration (FDA) as robust measurements for disease
diagnoses, clinical trials outcomes, and drug development.
The goal of this workshop was to better understand gaps
between clinical needs and probe development, and between
regulatory requirements and the reality of clinical transla-
tion, including the lack of commercial incentives for the
private sector. This report is intended to summarize
information presented at the meeting,1 focusing on the
examples discussed and citations provided by the partici-
pants, and on the conclusions of the panel sessions. While
the authors have included additional examples to those
provided by the participants, the goal of this report is to
summarize the outcome of the meeting, not to provide
exhaustive reviews for each of the topics mentioned. For
additional information on the meeting, interested readers are
encouraged to view the recording in the NIH videocast
archive2 and the NIBIB archive of the conference materials.3
Current Clinical Needs and Challenges
The ﬁrst session of this workshop focused on high-priority
clinical needs that could be addressed by the development of
suitable molecular imaging probes. The speakers focused on
(1) cardiovascular, (2) endocrine and metabolic, (3) neuro-
logic, and (4) inﬂammatory diseases. Probe development for
cancer was not speciﬁcally addressed due to the extensive
programs in this area already sponsored by the National
Cancer Institute.4
Cardiovascular Diseases
There was a consensus that probes are needed for speciﬁc,
high-risk patient categories in cardiovascular diseases
though image-based population screening is not warranted.
Identiﬁcation of Vulnerable Plaques
Patients with vulnerable coronary and carotid plaques are
at risk of acute myocardial infarction and stroke. Current-
ly, carotid atherosclerosis burden is assessed by measur-
ing luminal stenosis. State of the art clinical imaging of
the lumen of the coronary arteries include cardiac
computer tomographic angiography (CTA) for plaque
remodeling [1], 2-deoxy-2-[18F]ﬂuoro-D-glucose (18F-
FDG)-PET for inﬂamed plaque [2], three-dimensional B-
mode ultrasound (US) imaging for vessel wall volume
measurements [3], and optical computer tomography
(OCT) during coronary angiography for determination of
plaque erosion [4]. Several preclinical and proof-of-
concept techniques have shown promise in detecting
high-risk atherosclerotic plaques such as time-of-ﬂight
(TOF) bright-blood magnetic resonance imaging (MRI),
gadolinium contrast-enhanced black-blood MRI or 18F-
FDG-PET/CT [5–7], and contrast-enhanced US using
microbubbles [8]. Additional noninvasive and invasive
imaging techniques for detecting vulnerable coronary
plaques can be found in [9].
The challenge remains in identifying vulnerable
plaques in asymptomatic subjects using molecular imag-
ing probes and techniques that will help prevent acute
cardiovascular events and reduce current hospital admis-
sions and associated costs. While ultrasound imaging has
been used to examine carotid plaque properties, MRI and
CT can also detect the presence of plaques, and
radiolabeled tracers that target inﬂammation, thrombosis,
and proteolysis may help better characterize atheromatous
plaques.
Imaging Agents to Improve the Triage
of Emergency Department Patients With Chest
Pain
Standard emergency department (ED) practice for the triage
of chest pain patients involves a 24-h hospital stay for
electrocardiography and cardiac troponin evaluation follow-
ed by a nuclear stress test (i.e., radionuclide myocardial
perfusion imaging, MPI) or CTA [10]. Meta-analysis of
patient data has shown that coronary CTA is effective in
ruling out the ED patients with acute chest pain [11]. With
respect to MPI, imaging tracers that have high myocardial
extraction, a short myocardial residence time, and less
splanchnic uptake all resolvable in a shorter time period
are needed so that physicians can complete an entire stress/
rest study in less than 1 h. It was thought by participants that
this would have a considerable clinical impact by reducing
time and cost in ED’s.
Probes for Imaging the Biology of Peripheral
Artery Diseases
Peripheral artery disease (PAD) is a clinically neglected
condition. Because PAD does not affect only large vessels,
molecular imaging probes that provide a way to image the
biology of peripheral artery diseases (limb ischemia) may
offer an opportunity to develop effective drug therapies as
alternatives to surgical revascularization and interventional
catheter-based approaches. Current imaging of PAD is
aimed at anatomical and ﬂow in large vessels using
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contrast-enhanced ultrasound (CEUS) [12], contrast-en-
hanced MRA [13], or CTA [14].
Imaging Probes Targeting Myocardial
Fibroblasts
Myocardial disease from multiple etiologies result in
myocardial ﬁbrosis and lead to heart failure [15].
Because the development of ﬁbrosis is a dynamic
process involving myoﬁbroblasts and inﬂammation, mo-
lecular imaging probes targeting markers of these
processes may be potentially useful [16, 17]. Speciﬁc
molecular targets in myoﬁbroblasts amenable to imaging
are summarized in [18].
Metabolic Diseases
Common technical challenges for imaging metabolic diseases
include very low concentration of imaging targets from a
relatively immature biological palette and dynamic metabolic
processes.
Imaging Pancreatic Beta Cells
The loss in the function of pancreatic beta cells, followed by
subsequent cell death underlies type I diabetes. Therefore,
the ability to image mass, function, and inﬂammation of
endogenous beta cells, transplanted islets, and cell-based
replacements, as well as to assess the delivery of therapeutic
constructs are high-priority areas. This capability would aid
the differential diagnosis of diabetes, help design and test
prevention strategies and therapies, and help monitor an
individual’s response to therapy. Imaging techniques and
promising tracers and probes currently available in preclin-
ical setting to imaging pancreatic beta cells mass (BCM) and
related metabolic pathways are summarized in [19]; howev-
er, many questions need to be addressed before these
approaches can be utilized for noninvasive quantiﬁcation
of beta cell mass (BCM) in the native pancreas [20].
Imaging Human Brown Adipose Tissue
There are two types of adipose tissue: white and brown
adipose tissues. While accumulation of white adipose tissue
is associated with obesity, it has been shown that lean men
have more brown adipose tissue (BAT) than obese men [21],
and the metabolic activities of BAT can be protective against
diet-induced obesity [22]. Therefore, noninvasive measure-
ment of mass and metabolic activity can establish a better
understanding of BAT distribution and associated metabolic
activity in humans. Molecular imaging of BAT using PET,
SPECT, CT or MRI, or a combination of these imaging
modalities in concomitant with targeting tracers can be used
to assess different aspect of BAT metabolic activities [23].
Imaging Organ Fibrosis
Nonalcoholic fatty liver disease (NAFLD) can progress in a
small fraction of people to cirrhosis and liver cancer. The
ability to noninvasively image early inﬂammation and
ﬁbrosis would allow staging of NAFLD with identiﬁcation
of people having an elevated risk of progression. Molecular
imaging probes and technology are needed to provide a
means to differentiate pathological ﬁbrosis from normal
aging and to correlate ﬁbrosis with disease progression, and
monitoring response to therapies. Current state of the art
imaging capability such as MR elastography [24] is not as
likely to be as useful in ﬁbrosis detection for the kidney,
prostate, and bladder. An additional confound is that kidney
and bladder cells tend to accumulate imaging agent upon
excretion, making it difﬁcult to image these tissues with
external agents.
Neurological Diseases
There are a number of neurodegenerative diseases with
partially-overlapping symptomatology and underlying mo-
lecular pathology. Accurate diagnosis has important impli-
cations not only for patient outcomes, but also in avoidance
of iatrogenic morbidity, reduction of healthcare costs, and in
the correct assignment of patient populations in clinical
trials. Development of molecular imaging probes for
disease-speciﬁc molecular targets can help provide deﬁnitive
diagnoses. The approval of 18F-Florbetapir by the FDA for
the diagnosis of Alzheimer’s disease (AD) highlights the
need for comparably biomarker-speciﬁc agents for the
diagnosis of other neurological diseases. This will also
facilitate the development of disease-modifying therapies for
neurodegenerative and other neural diseases.
Imaging Probes Targeting Tau Aggregate
Subtypes and α-Synuclein
Endophenotyping of patients early in neurodegenerative
dementia is clinically difﬁcult but necessary for the
discovery and testing of effective new therapies. There are
three pivotal biomarkers associated with various neurode-
generative diseases which include the presence of Aβ-
amyloid, tau tangles, and α-synuclein. Currently available
PET tracers for molecular endophenotyping of neurodegen-
erative dementia and movement disorders include 18F-FDG
for the assessment of cerebral glucose metabolism, [11C]-
PiB for the ﬁbrillar Aβ-amyloid deposition and [11C]-DTBZ
for the evaluation of nigrostriatal dopaminergic projection
terminals [25–30]. Although 18F-Florbetapir for PET imag-
ing of Aβ-amyloid has been approved for the diagnosis of
AD, molecular imaging probes for diagnosing other protein
deposits associated with various human neurodegenerative
diseases are still lacking. Tracers are needed to distinguish
among diseases associated with the presence of α-synuclein
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aggregates (Parkinson’s disease vs. multiple system atrophy)
and tau tangles (progressive supranuclear palsy vs.
corticobasal degeneration). Tracers are also needed to
distinguish among neurodegenerative dementia subtypes.
Imaging Probes to Assess Neuronal Integrity
Although MR diffusion tensor imaging (DTI) can determine
regions of compromised white matter tract integrity, there is
currently no effective tracer to objectively measure vulner-
able neurons. This represents a research opportunity that
should advance our understanding of neuronal function loss.
Imaging Probes to Assess Endogenous Synaptic
Neurotransmitter Levels
Currently available PET probes are used to evaluate the
health of endogenous dopamine and opiate systems. For
example, we have [11C]-raclopride (and others targeting
dopamine receptors) which are used to evaluate the health of
endogenous dopamine system and [11C]-carfentanyl to
assess endogenous opiate peptide levels and release [31].
Molecular imaging probes that can measure other neuro-
transmitters are needed (e.g., glutamate, gamma-
aminobutyric acid (GABA), and serotonin).
Imaging Probes to Assess Chronic Brain
Inﬂammation
Chronic inﬂammation of the brain has been implicated in
many neurodegenerative diseases [32]. Symptoms include
increased blood–brain barrier (BBB) permeability, systemic
white blood cell recruitment, and microglial activation
(reactive gliosis). Currently available tracers to detect these
symptoms include [68Ga] EDTA for the BBB disruption [33,
34], [11C]-AMT for inﬂammatory cellular response [35],
[11C]-deprenyl for reactive astrocytes [36], and [11C]-PBR28
for mitochondrial translocator protein (TSPO) associated
with oxidative stress status [37].
Neuroimaging Associated with Obesity
and Diabetes
Chronic metabolic diseases upset energy and homeostasis in
the body and the brain; this imbalance is implicated in both
disease onset and further altered by disease states. Neuro-
imaging probes and technologies are needed to assess (1)
density and function of hormone receptors in the human
brain (e.g., insulin, glucagon, leptin, ghrelin, and sex
hormones), (2) altered nutrient-sensing pathways, (3)
neurotransporters and receptors in the hypothalamus, (4)
active sites of obesity drugs, (5) mechanisms whereby
atypical antipsychotics cause obesity, and (6) the relation-
ship between dementia and diabetes.
Inﬂammatory Diseases
Because inﬂammation underlies mechanisms for a number
of diseases and clinical conditions, molecular imaging
probes that identify targets in this process are likely to have
broad applicability. Discussion of this area focused on the
widespread importance of inﬂammatory processes in rheu-
matology, cancer, cardiovascular diseases, as well as a
number of other diseases, and the current paucity of speciﬁc
imaging probes. One example was given of chemokine
receptors that play a fundamental role in the migration of
progenitor cells during embryonic development of the
cardiovascular, vascular, hematopoietic, and central nervous
systems, and are associated with more than 23 types of
human cancers. Molecular imaging of antagonists of
chemokine receptors could allow for the visualization of
speciﬁc leukocytes subsets in tissue that could be of value in
studying, diagnosing, and treating infectious and inﬂamma-
tory diseases.
Advances in Molecular Probe Design
The second session focused on recent developments in
molecular imaging probe design that could help address the
clinical needs identiﬁed in the ﬁrst session. The speakers
focused on technical developments that promise increases in
diagnostic sensitivity, or speciﬁcity.
MRI Probes
Molecular imaging with MRI presents special challenges.
While biomarkers of interest often are present in 10−6 to 10−12
molar concentration, the sensitivity of magnetic resonance
(MR) contrast agents is in 10−3 to 10−5 molar concentration
range. Hence, signal ampliﬁcation is required to bridge the gap,
and also forms the biggest challenge in MR probe design.
Paramagnetic metals such as gadolinium, Gd(III), and iron
oxide, Fe(II), are regularly utilized in molecular imaging. Most
Gd-based MR contrast agents are small, single ions which
produce low signal enhancement. Efforts have been made to
compensate such shortcoming by manipulating the rotational
correlation or water exchange rate of single or clusters of
Gd(III) [38]. Recent development of Gd compounds involves
nanoplatforms (e.g., dendrimers, liposomes, polymersomes,
micelles, emulsions, carbon, or silica nanoparticles) which can
carry high payload of chelated Gd to achieve much-improved
relaxivity [39]. Among the techniques for encapsulating Gd
ions, the porous vesicle membrane design was shown to
facilitate water-exchange rate of Gd(III) and increase the
overall relaxivity [40]. Superparamagnetic iron oxide nanopar-
ticles (SPION) contain 6,000 to 9,000 iron per particle and
provide strong signal contrast by localized reduction of MR
signals [41]. Clustered iron oxide nanoparticles generates more
pronounced signal reduction in T2*-weighted images [42].
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Another important challenge for MR contrast agent design
is to generate bioactivated and theranostic agents that can be
used in complex, physiological conditions. Bioactivated MR
agents can be utilized to report enzymatic activities [43, 44],
gene expression (e.g., β-galactosidase [45], β-glucoronidase,
caspases [46], metalloproteinases (MMPs) (e.g., [47, 48])) as
well as signal transduction and intracellular messengers such as
Ca2+ [49] and Zn2+ (e.g., [50, 51]). It was observed that
currently all MR-based molecular imaging probes are for
preclinical and investigational use only.
PET Probes
Discussion of molecular imaging probes labeled with PET
isotopes focused on meeting the needs for neurodegenerative
diseases. Speciﬁc examples were discussed including Eli Lilly’s
ﬂorbetapir/Amyvid which was approved by the FDA for clinical
imaging of Aβ-amyloid in the US in April of 2012 [52, 53]; GE
Health Care and Piramal have submitted new drug application
(NDA) to FDA for ﬂutemetamol and ﬂorbetaben [54] and a
phase III trial is planned by Navidea for AZD4694 in 2014 [54].
The Center for Medicare andMedicaid Services (CMS) recently
reviewed Medicare coverage for amyloid β imaging and
recommended further study to demonstrate improved patient
outcomes following diagnostic imaging or imaging to monitor
disease progression. With regard to imaging α-synuclein
deposits which are present in neurons of Dementia with Lewy
Bodies (DLB) and Parkinson’s disease (PD) patients, the
development of selective agents for α-synuclein imaging
remains a challenge. PET radioligands needed for additional
neurodegenerative proteopathies include agents to detect
hyperphosphorylated TDP-43 (associated with amyotrophic
lateral sclerosis, ALS), huntingtin (associated with Huntington’s
disease), and prions (associated with diseases such as
Creutzfeldt-Jakob disease, Kuru, and Alpers’ syndrome).
A currently available radioligand for the detection of CNS
inﬂammation is [11C]-PK11195 [55, 56]. PK11195 was ﬁrst
shown to have brain binding capability in 1983 [57]. However,
this radioligand has several limitations which include low in
vivo speciﬁc binding, thus signal speciﬁcity is low [58]. Several
additional TSPO-targeting radioligands developed in the past
10 years have offered incremental improvement in speciﬁc
binding [59, 60]. There are a limited number of published
studies of new TSPO radioligands in clinical populations
showing potential in MS evaluations [61, 62]. Possible
confounds in the development of TSPO-speciﬁc radioligands
is the existence of TSPO polymorphism even in the control
subjects [63–65]. Possible probe designs for the detection of
CNS inﬂammation may target microglial activation markers
such as P2X2, MMP, COS-2, H4 CB2, MAO-B, etc.
Ultrasound Probes
The primary challenge in molecular ultrasound (US)
imaging is the image resolution, a spatial scale difference
of six orders of magnitude between anatomical resolution (of
10−3 m) and molecular resolution (10−9 m). Another
limitation of molecular ultrasound is that currently available
US contrast agents have sizes of the order of 10−6 m and are,
therefore, largely limited to targets within the vascular
compartment. Photoacoustic (PA) imaging has emerged as
a promising approach because it offers the penetration depth
of US and resolution comparable to optical imaging [66].
Nanoparticle-augmented US/PA imaging can overcome the
contrast imaging agent size challenge and has been used for
the molecular imaging of cancer [66]. The development of
molecular ultrasound imaging requires not only probe design
but also hardware and software development [67]. Several
companies have made available USPA imaging systems to
research communities including Visulasonics, Endra, and
iThera Medical. Current preclinical application of USPA
imaging probes includes the use of epidermal growth factor
receptor (EGFR)-targeting plasmonic gold nanosphere for
the detection of EGFR-positive and metastatic tumor cells in
mice [68]. USPA imaging can also be used to image lipid
and microphages associated with atherosclerosis [69–71].
Using gold nanoparticles and USPA imaging, it is possible
to track the proliferation, and differentiation of stem cells is
possible [72]. Another photoacoustic contrast agent consists
of perﬂuorocarbon nanodroplets; this agent can be activated
by laser to generate signal and enhance image contrast [73].
Molecular US probes have the potential to be “smart” or
activatable, biocompatible, nontoxic, and clinically relevant
or translatable, and multimodal imaging approaches like
magnetomotive US [74–76], and magneto-photo-acoustics
[77] are promising.
Multimodality and Multifunctional Probes
Multimodality agents can provide synergistic information by
leveraging the beneﬁts of two or more imaging modalities in
serial or concurrent session. Multifunctional agents can, in
principle, improve efﬁciency by enabling detection and
treatment in one session. The advantages of generating low
molecular weight imaging compounds (G1,000 Da) include
(1) established chemistry, (2) easy to characterize, (3)
homogenous, (4) easy penetration, and (5) clearer path to
clinical use. On the other hand, the advantages of generating
more complex multiplexed imaging agents (G100 nm)
include higher surface area/volume ratio, ﬂexible platform,
potential increase in the therapeutic index, and tunable
pharmacokinetics.
Several examples of multimodality and multifunctional
probes were presented. One example consisted of the
conjugation of a dual-modality (SPECT/NIRF) imaging
agent to a prostate-speciﬁc membrane antigen (PSMA)-
targeting urea, which enables sequential, dual modality
imaging of experimental prostate tumors at radiotracer level
(1–10 nmol) [78]. A proof-of-concept study demonstrated
the feasibility in theranostic imaging of metastatic prostate
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using a dual-modality (SPECT/CT) nanoplex containing
multimodal imaging reporters targeting PMSA. The
nanoplex was designed to deliver small interfering RNA
(siRNA) along with a prodrug enzyme to PSMA-expressing
tumor [79]. Polymeric nanoparticles have the ability to
accumulate within the tumor interstitium and have the
potential for targeting therapy. Based on this observation,
PSMA-targeting, docetaxel (Taxotere)-loaded polymer
nanoparticles were shown to have selective cytotoxicity
against PSMA-producing cells [80] and cause tumor
shrinkage in phase 1 trial [81].
The concept of molecular-genetic imaging was introduced
several years ago which allows imaging of gene expression
directly or indirectly. For example, in vivo mouse imaging of
herpes simplex virus type 1 thymidine kinase (HSV1-tk) gene
expression was demonstrated using [124I]-FIAU [82, 83] with
PET. Labeled FIAU with [125I] or [131I] may have potential to
be a theranostic agent. Progression elevated gene-3 promoter
(PEG-Prom) can be used to drive imaging reporters to detect
micrometastatic disease [84]. Challenges identiﬁed by the
participants for the complex agents include (1) designing dual
PET/MR probes with combined chemistry under solid and
solution phases, (2) establishing a useful balance between the
different sensitivities of PET and MR agents, and (3)
maintaining probe afﬁnity and speciﬁcity after labeling with
PET and MR signal-generating moieties.
It was concluded during the discussion after the ﬁrst two
sessions that although a number of PET and SPECT probes
have been studied in humans, most molecular imaging probes
remain in preclinical or limited investigational use. A number of
possible reasons for this state of affairs were discussed. While
some of the probes have promising speciﬁcity, nonspeciﬁc
binding (especially in the CNS) is in most cases still suboptimal
for the challenges of regulatory approval and eventual everyday
clinical use. For probes with peripheral targets, accumulation in
the liver, kidneys, and suboptimal blood clearance continue to
present challenges. Some of the speakers noted that while the
probe development community had good communication, there
needed to be closer cooperation between academic researchers,
clinicians, industry, and regulators, such as the cooperation that
led from the discovery of PiB to the eventual development and
FDA approval of ﬂorbetapir.
A vigorous discussion centered on the possible advan-
tages of multimodality and multifunctional probes. While
the panel participants, upon questioning by members of the
audience, reiterated the advantages and challenges originally
enumerated, no clear consensus emerged in this area.
Multimodality probe development has been pursued and
continues unabated, but there a most promising translational
path was not identiﬁed.
Current Needs and Challenges
for Industry
The third session addressed clinical needs from the perspec-
tive of the challenges faced during pharmaceutical
development. In this context, molecular imaging probes
can be used as pharmacokinetic indicators to accelerate the
screening of promising drug candidates, or they can be used
as surrogate biomarkers for pharmaceutical efﬁcacy.
There are several challenges in the clinical translation of
new drugs. For instance, it can cost between $300–400
million and an average of 6.5 years for early research/
preclinical testing before an investigational new drug (IND)
application is ﬁled. An additional 6–10 years on average and
$200–300 million are needed to get a drug through clinical
trials [85]. There has been a dramatic increase in attrition
rates in phase II and phase III clinical trials [86]. Improving
R&D efﬁciency and productivity depends strongly on
reducing phase II and III attrition, hence the design of phase
II trial is critical [87]. The reasons for this increased failure
rate during pharmaceutical development include (1) lack of
efﬁcacy, (2) toxicity, (3) poor drug metabolism and
pharmacokinetic proﬁles, (4) paucity of new drug targets,
(5) strategic reasons such as competition and risk/beneﬁt
ratios, and ﬁnally (6) market failure [88]. PET molecular
imaging provides direct quantitative measurement to accel-
erate drug development. Precision medicine including
imaging and genetics can mitigate risks involved in clinical
trials. For example, PET imaging is used to perform receptor
occupancy studies in the CNS for the reason that receptor
occupancy study is the only way to directly conﬁrm target
engagement and can help prioritize candidates for advance-
ment to clinic. Pharmaceutical companies also utilize
preclinical PET imaging extensively to assess mechanism
and therapeutic efﬁcacy, e.g., see [89]. Recently, there is a
signiﬁcant increase in academic/industrial partnership
around imaging biomarkers, as well as resources/funding/
consortia available for academic-industrial partnerships.
Consortia in particular continue to set standard for imaging
and optimize preclinical models. In conclusion, PET
molecular imaging is the future of drug development which
can save both time and money in the selection of targets,
conﬁrmation of mechanisms, dosage selection, and the
overall evaluation of candidate drugs in their development.
The exploratory IND has provided an efﬁcient mecha-
nism for evaluating investigational radiopharmaceuticals in
humans, including the speciﬁc disease indication in which
the test imaging tracer might be used. An exploratory IND
will allow for preliminary human studies in a limited number
of subjects to perform within subject comparison of
structurally-related radiopharmaceuticals, as well as dis-
placement/occupancy studies. This is yet another way in
which imaging agents (typically PET molecularly targeted
agents) are routinely utilized by pharmaceutical companies
in the development of disease-modifying agents. The
imaging agents themselves often remain at the eIND stage,
and may not reach full FDA approval as imaging agents for
humans.
To collect sufﬁcient human data in clinical studies
requires (1) good manufacturing practice (GMP)-certiﬁed
chemistry production, (2) recruitment of healthy subjects and
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patients in a dedicated research unit with inpatient facilities,
(3) image processing capability, (4) regulatory support for
clinical trial, IND and institutional review board (IRB)
management, and (5) data/project management support. A
multidisciplinary team encompassing experts in chemistry,
clinical setup, imaging, data management, and regulatory
guidelines is needed to efﬁciently validate and translate new
molecular imaging agents for clinical use but can be difﬁcult
to assemble in practice. Two examples were presented to
illustrate the steps that Molecular Neuroimaging, LLC
undertakes in testing agents for central nervous system
diseases, [18F]-MNI-659 targeting PDE10A to study
Huntington’s disease using PET and [123I]-MNI-420
targeting adenosine A2a receptor for CNS diseases using
SPECT [90–92].
Given the challenges faced by the pharmaceutical
development process, the activities provided by the NCI
Experimental Therapeutics (NExT) program5 were present-
ed, highlighting support of drug development and registra-
tion. The activities currently supported by NExT resources
include investigational drugs and biologics; investigational
imaging agents, academic, biotechnology and pharmaceuti-
cal projects, phase 0, 1 and 2 clinical trials, and high-
throughput screening; and hit-to-lead and lead optimization.
A particularly important concept supported by NExT is that
of “shared” INDs. In “shared” INDs, all but the clinical
aspects of the IND application can be “imported” from
someone else’s IND by a letter of right of reference. The
advantages of shared INDs are to avoid the cost and animal
burden of repetitive toxicology studies, to save the work
needed to organize and present several sections of an IND,
to reduce uncertainty as the result of not knowing what FDA
has accepted, and ﬁnally to save FDA review time so the
review can focus on clinical trials. Imaging probes may
potentially be classiﬁed as orphan drugs with appropriately
strong justiﬁcations. FDA offers orphan products grant
program for drugs, biologics, medical devices, or medical
foods, available to domestic and foreign, public or private,
for proﬁt or nonproﬁt entities.6
Clinical Translation of Molecular
Imaging Probes
The ﬁnal session provided discussion of the regulatory
perspective that accompanies clinical translation of molecu-
lar imaging probes. The session included an example of
successful translation and was accompanied by perspectives
from representatives from US Federal Government regula-
tory agencies.
As an example of the successful “bench to bedside”
translation of a molecular imaging probe, participants
discussed the process and challenges in getting to ﬁrst-in-
human testing of hyperpolarized (HP) [13C]-pyruvate for
prostate cancer imaging. It took the University of California
at San Francisco (UCSF) researchers 10 years to go from the
ﬁrst technology paper on dynamic nuclear polarization
(DNP) to IND approval by the FDA for hyperpolarized
[13C]-pyruvate and subsequent NIH funding of a phase I
clinical trial in prostate cancer patients [93]. Challenges that
had to be overcome included the (1) development of a sterile
setup to generate and deliver HP [13C]-pyruvate reproduc-
ibly and efﬁciently to humans, (2) development of pharma-
ceutical compounding standard operating procedures for
pharmacy technicians to produce doses routinely and in a
clean room, (3) creation of a physiologically compatible 13C
MRI radiofrequency (RF) coil with MR imaging protocol
and analysis methods [94, 95], (4) establishment of safety
and potential patient beneﬁt for IRB and FDA approval, and
(5) coordination of expertise from various disciplines from
academia, clinical management, and industry.
The FDA noted that including imaging in a clinical trial
can provide assurance that subjects have the deﬁned
condition, assess if patients are likely to respond to the
investigational drug, and potentially shortening the time
needed to demonstrate efﬁcacy of diagnostic or therapeutic
drugs for FDA approval. Imaging standards in clinical trials
should include standardized acquisition and interpretation to
control potential sources of bias and variability and
veriﬁcation of data quality and integrity. To establish
efﬁcacy in clinical studies of imaging drugs, the FDA
recommends that the anatomic, functional, or physiological
measurements using an imaging agent be compared with
those of a reference products or procedures or a known true
standard. If no standard of truth is available, the FDA
recommends that a clinical trial be conducted in order to
determine the clinical usefulness. To establish effectiveness
of therapeutic drugs using imaging, applicants should
consider endpoint meaningfulness, determine applicable
imaging standards, and most importantly consult FDA
reviewers as early as possible. In sum, the key points for
implementing imaging in phase 3 clinical trials are (1)
adequate, well-controlled investigations, (2) well-deﬁned
and reliable methods of response assessment, (3) imaging
standardization, and (4) an endpoint with consideration in
meaningfulness continuum (i.e., self-evident/established
beneﬁt, reasonably likely to predict beneﬁt, bioactivity/
pharmacodynamics).
An important consideration in molecular imaging probe
development, following FDA approval, is reimbursement. A
representative from CMS raised a number of important
points concerning Medicare coverage of diagnostic tests, as
they apply to molecular imaging probes: (1) diagnostic tests
are rarely therapeutic; (2) diagnostic testing may expose a
patient to speciﬁc short- or long-term risks; (3) while
potential harm may occur, diagnostic tests accrue beneﬁts
and can inform downstream clinical management of the
patients (4) balance of risk and harm should consider the
acuity and severity of the patient’s presentation; (5)
5http://next.cancer.gov
6http://www.fda.gov/orphan
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avoidance of unnecessary or futile treatment can improve
health outcomes; and (6) Medicare does not consider cost in
making national coverage decisions. A preferred road to
diagnostic coverage should provide adequate evidence that
the incremental information obtained by new diagnostic
technology, compared to alternatives, changes physician
recommendations. In particular, this should result in changes
in therapy that improve clinically meaningful health out-
comes in Medicare beneﬁciaries.
Conclusions
In the presentation and discussion sessions, the workshop
participants identiﬁed pressing clinical needs and develop-
ment opportunities for molecular imaging probes in cardio-
vascular, endocrine, neurologic, and inﬂammatory diseases,
which complement the existing vigorous cancer imaging
programs. Conventional nuclear medicine probes as well as
novel MRI contrast agents, US and multimodality ap-
proaches appear promising for different applications. Indus-
try representatives stressed the need for continued
collaboration between academic, government, and industry
sectors in these efforts, and noted that molecular imaging
probe success should be measured both by the collection of
probes that serve to help screen for disease-modifying
therapies in preclinical settings, as well as the smaller
number that emerge as FDA-approved imaging agents.
Participants also observed that standardization and validation
of protocols in order to obtain regulatory approval for
clinical translation of molecular imaging probes and tech-
nology is an achievable and desirable goal.
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